The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
The path to a successful vaccine adjuvant – ‘The long and winding road’
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide
Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H., & Lee, J.-O. (2007) · Cell · doi:10.1016/j.cell.2007.09.008 · Cited by 1,344
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Kim, H. M., Park, B. S., Kim, J.-I., Kim, S. E., Lee, J., Oh, S. C., Enkhbayar, P., Matsushima, N., Lee, H., Yoo, O. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.002 · Cited by 1,177
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90458-6 · Cited by 1,019
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
The inflammasome: a danger sensing complex triggering innate immunity
Pétrilli, V., Dostert, C., Muruve, D. A., & Tschopp, J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.09.002 · Cited by 700 · cited 1×
“20, 377–382 69 Petrilli, V. et al. (2007) The inflammasome: a danger sensing complex triggering”
BackgroundCutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3
Li, H., Willingham, S. B., Ting, J. P.-Y., & Re, F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.17 · Cited by 675
Liposomes as immunological adjuvants
ALLISON, A. C., & GREGORIADIS, G. (1974) · Nature · doi:10.1038/252252a0 · Cited by 675
Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
The perfect mix: recent progress in adjuvant research
Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 620
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B., & Nemazee, D. (2006) · Science · doi:10.1126/science.1135299 · Cited by 581
Identification of Bacterial Muramyl Dipeptide as Activator of the NALP3/Cryopyrin Inflammasome
Martinon, F., Agostini, L., Meylan, E., & Tschopp, J. (2004) · Current Biology · doi:10.1016/j.cub.2004.10.027 · Cited by 579
Pathogen recognition with Toll-like receptors
Kawai, T., & Akira, S. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.02.007 · Cited by 576
MDA5/RIG-I and virus recognition
Takeuchi, O., & Akira, S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.01.002 · Cited by 570
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Sharp, F. A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 540
Self-citationLeroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M., & Leroux-Roels, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61297-5 · Cited by 498
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Self-citationCorey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, Jr., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., et al. (1999) · JAMA · doi:10.1001/jama.282.4.331 · Cited by 490
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Vaccine design : the subunit and adjuvant approach
Powell, M. F., Newman, M. J., & Burdman, J. R. (1995) · Plenum Press eBooks · Cited by 451
Franchi, L., & Núñez, G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838549 · Cited by 450
Recent advances in the discovery and delivery of vaccine adjuvants
O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434
Self-citationSeubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Self-citationImmunological notes. XVII–XXIV
Glenny, A. T., Pope, C. G., Waddington, H., & Wallace, U. (1926) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700290106 · Cited by 399
Triggering TLR signaling in vaccination
van Duin, D., Medzhitov, R., & Shaw, A. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Vaccination and autoimmune disease: what is the evidence?
Wraith, D. C., Goldman, M., & Lambert, P.-H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14802-7 · Cited by 362
Fritz, J. H., Girardin, S. E., Fitting, C., Werts, C., Mengin-Lecreulx, D., Caroff, M., Cavaillon, J.-M., Philpott, D. J., & Adib-Conquy, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200526286 · Cited by 358
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.002 · Cited by 334
Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release
Li, H., Nookala, S., & Re, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5271 · Cited by 332
Sensitization and Antibody Formation after Injection of Tubercle Bacilli and Paraffin Oil.
Freund, J., Casals, J., & Hosmer, E. P. (1937) · Experimental Biology and Medicine · doi:10.3181/00379727-37-9625 · Cited by 311
NOD-like receptors (NLRs): bona fide intracellular microbial sensors
Shaw, M. H., Reimer, T., Kim, Y.-G., & Nuñez, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.001 · Cited by 298
Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
Morefield, G. L., Sokolovska, A., Jiang, D., HogenEsch, H., Robinson, J. P., & Hem, S. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.07.050 · Cited by 293
O’Hagan, D. T. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.699 · Cited by 282
Self-citationBiodegradable microparticles as controlled release antigen delivery systems.
O’Hagan, D. T., Rahman, D., McGee, J. P., Jeffery, H., Davies, M. C., Williams, P. M., Davis, S. S., & Challacombe, S. (1991) · PubMed Central · Cited by 270
Self-citationAntigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
Boscardin, S. B., Hafalla, J. C. R., Masilamani, R. F., Kamphorst, A. O., Zebroski, H. A., Rai, U., Morrot, A., Zavala, F., Steinman, R. M., Nussenzweig, R. S., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051639 · Cited by 269
Edelman, R. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.3.370 · Cited by 245
O'Hagan, D. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00012-x · Cited by 243
Self-citationUlanova, M., Tarkowski, A., Hahn-Zoric, M., & Hanson, L. Å. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1151-1159.2001 · Cited by 239
Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine
Stoute, J. A., Kester, K. E., Krzych, U., Wellde, B. T., Hall, T., White, K., Glenn, G., Ockenhouse, C. F., Garcon, N., Schwenk, R., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515657 · Cited by 236
Alum adjuvanticity: Unraveling a century old mystery
De Gregorio, E., Tritto, E., & Rappuoli, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200838648 · Cited by 232
Self-citationSchultze, V., D’Agosto, V., Wack, A., Novicki, D., Zorn, J., & Hennig, R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.093 · Cited by 227
Vandepapelière, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.038 · Cited by 218
A Compendium of Vaccine Adjuvants and Excipients
Vogel, F. R., & Powell, M. F. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_7 · Cited by 217
Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H., Ugozzoli, M., Singh, M., Kazzaz, J., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.054 · Cited by 195
Self-citationBridging the knowledge gaps in vaccine design
Rappuoli, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1361 · Cited by 185
Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection
Dupuis, M., Murphy, T. J., Higgins, D., Ugozzoli, M., van Nest, G., Ott, G., & McDonald, D. M. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1283 · Cited by 185
Wille-Reece, U., Wu, C.-Y., Flynn, B. J., Kedl, R. M., & Seder, R. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7676 · Cited by 185
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
Fully mobilizing host defense: Building better vaccines
Raychaudhuri, S., & Rock, K. L. (1998) · Nature Biotechnology · doi:10.1038/3469 · Cited by 175
Straus, S. E., Wald, A., Kost, R. G., McKenzie, R., Langenberg, A. G. M., Hohman, P., Lekstrom, J., Cox, E., Nakamura, M., Sekulovich, R., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514103 · Cited by 169
The global impact of vaccines containing aluminium adjuvants
Clements, C. J., & Griffiths, E. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00168-8 · Cited by 164
Rimaniol, A., Gras, G. S., Verdier, F., Capel, F., Grigoriev, V. B., Porcheray, F., Sauzeat, E., Fournier, J. G., Clayette, P., Siegrist, C., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.061 · Cited by 157
The mode of action of mineral-oil emulsion adjuvants on antibody production in mice.
Herbert, W. J. (1968) · PubMed · Cited by 155
Verstraeten, T., Descamps, D., David, M., Zahaf, T., Hardt, K., Izurieta, P., Dubin, G. O., & Breuer, T. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.049 · Cited by 155
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis
Dupuis, M., Denis-Mize, K. S., LaBarbara, A., Peters, W., Charo, I. F., McDonald, D. M., & Ott, G. S. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<2910::aid-immu2910>3.0.co;2-3 · Cited by 145
Kazzaz, J., Neidleman, J. A., Singh, M., Ott, G. S., & O’Hagan, D. T. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00226-1 · Cited by 127
Self-citationEncapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency
Kazzaz, J., Singh, M., Ugozzoli, M., Chesko, J., Soenawan, E., & O’Hagan, D. T. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.010 · Cited by 120
Self-citationThe use of oil adjuvants in therapeutic vaccines
Aucouturier, J., Ascarateil, S., & Dupuis, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.116 · Cited by 120
Levie, K., Leroux‐Roels, I., Hoppenbrouwers, K., Kervyn, A., Vandermeulen, C., Forgus, S., Leroux-Roels, G. G., Pichon, S., & Kusters, I. C. (2008) · The Journal of Infectious Diseases · doi:10.1086/590913 · Cited by 116
Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA
Singh, M., Ott, G. S., Kazzaz, J., Ugozzoli, M., Briones, M., Donnelly, J., & O’Hagan, D. T. (2001) · Pharmaceutical Research · doi:10.1023/a:1012269226066 · Cited by 115
Self-citationMicroparticles as potentially orally active immunological adjuvants
O’Hagan, D. T., Palin, K. J., Davis, S. S., Artursson, P., & Sjöholm, I. (1989) · Vaccine · doi:10.1016/0264-410x(89)90156-4 · Cited by 115
Self-citationHeineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
A Practical Approach to the use of Nanoparticles for Vaccine Delivery
Wendorf, J. R., Singh, M., Chesko, J., Kazzaz, J., Soewanan, E., Ugozzoli, M., & O’Hagan, D. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20728 · Cited by 100
Self-citationToll-like receptors and antibody responses
Nemazee, D. A., Gavin, A. L., Hoebe, K. H. N., & Beutler, B. (2006) · Nature · doi:10.1038/nature04875 · Cited by 97
Singh, M., Ugozzoli, M., Kazzaz, J., Chesko, J., Soenawan, E., Mannucci, D., Titta, F., Contorni, M., Volpini, G., & Guidice, G. D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.09.046 · Cited by 92
E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant
Ishizaka, S. T., & Hawkins, L. D. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.773 · Cited by 91
O’Hagan, D. T., Wack, A., & Podda, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100402 · Cited by 90
Self-citationSingh, M., Li, X.-M., Wang, H., McGee, J. P., Zamb, T. J., Koff, W. C., Wang, C. Y., & O’Hagan, D. T. (1997) · Infection and Immunity · doi:10.1128/iai.65.5.1716-1721.1997 · Cited by 84
Self-citationDavenport, F. M., Hennessy, A. V., & Askin, F. B. (1968) · The Journal of Immunology · doi:10.4049/jimmunol.100.5.1139 · Cited by 81
Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man.
Davenport, F. M., Hennessy, A. V., & Askin, F. B. (1968) · PubMed · Cited by 77
Eickhoff, T. C., & Myers, M. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00163-9 · Cited by 76
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems
Wendorf, J. R., Chesko, J., Kazzaz, J., Ugozzoli, M., Vajdy, M., O’Hagan, D. T., & Singh, M. (2008) · Human Vaccines · doi:10.4161/hv.4.1.4886 · Cited by 75
Self-citationSingh, M., Kazzaz, J., Chesko, J., Soenawan, E., Ugozzoli, M., Giuliani, M. M., Pizza, M., Rappouli, R., & O’Hagan, D. T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10538 · Cited by 72
Self-citationCataldo, D. M., & Nest, G. V. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00115-1 · Cited by 54
Clinical experience with inactivated, virosomal influenza vaccine
de Bruijn, I. A., Nauta, J. J. P., Cramer, W., Gerez, L., & Palache, A. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.020 · Cited by 53
Vajdy, M., Selby, M., Medina-Selby, A., Coit, D., Hall, J. E., Tandeske, L., Chien, D. C., Hu, C., Rosa, D., Singh, M., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81849-0 · Cited by 49
Self-citationVaccine Immunopotentiators of the Future
Schijns, V. E. J. C., & Degen, W. G. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100394 · Cited by 44
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Minireview: Nanoparticles and the Immune System
Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914
Modulating immunity as a therapy for bacterial infections
Hancock, R. E. W., Nijnik, A., & Philpott, D. J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2745 · Cited by 535
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Self-citationNew adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Self-citation
Metadata
- Authors
- O’Hagan, D. T., & De Gregorio, E.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 14
- Issue
- 11-12
- Pages
- 541-551
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1997117545
- Cited by
- 274
- References
- 86
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.